IMAXIO has a total of 20 patent applications. Its first patent ever was published in 2004. It filed its patents most often in United States, Canada and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are VACCIBODY AS, THROMBOSIS RES INST and BIOSCEPTRE UK LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | Canada | 3 | |
#3 | China | 3 | |
#4 | WIPO (World Intellectual Property Organization) | 3 | |
#5 | Brazil | 2 | |
#6 | EPO (European Patent Office) | 2 | |
#7 | Republic of Korea | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Hill Fergal | 18 |
#2 | Del Campo Ascarateil Judith | 11 |
#3 | Turki Hani Imene | 5 |
#4 | Marchand Jean-Baptiste | 5 |
#5 | Dumon Laurence | 5 |
#6 | Fergal Hill | 2 |
#7 | Judith Del Campo Ascarateil | 2 |
#8 | Imene Turki Hani | 1 |
Publication | Filing date | Title |
---|---|---|
CN105143251A | Influenza nucleoprotein vaccines | |
WO2014090905A1 | Modified coiled coil type proteins having improved properties | |
EP1795540A1 | Multimeric complexes of antigens and an adjuvant |